JPH11511983A - 細胞表面における物質の付着およびディスプレイに関連する材料および方法 - Google Patents
細胞表面における物質の付着およびディスプレイに関連する材料および方法Info
- Publication number
- JPH11511983A JPH11511983A JP9510983A JP51098397A JPH11511983A JP H11511983 A JPH11511983 A JP H11511983A JP 9510983 A JP9510983 A JP 9510983A JP 51098397 A JP51098397 A JP 51098397A JP H11511983 A JPH11511983 A JP H11511983A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- gram
- host organism
- positive
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 43
- 210000004027 cell Anatomy 0.000 title claims description 103
- 239000000126 substance Substances 0.000 title claims description 14
- 239000000463 material Substances 0.000 title description 7
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 168
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 155
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 68
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 64
- 229920001184 polypeptide Polymers 0.000 claims abstract description 63
- 230000014509 gene expression Effects 0.000 claims abstract description 35
- 239000013598 vector Substances 0.000 claims abstract description 29
- 210000002421 cell wall Anatomy 0.000 claims description 48
- 108020001507 fusion proteins Proteins 0.000 claims description 39
- 102000037865 fusion proteins Human genes 0.000 claims description 39
- 102000004190 Enzymes Human genes 0.000 claims description 38
- 108090000790 Enzymes Proteins 0.000 claims description 38
- 108010090804 Streptavidin Proteins 0.000 claims description 37
- 229940088598 enzyme Drugs 0.000 claims description 34
- 230000004927 fusion Effects 0.000 claims description 31
- 239000003446 ligand Substances 0.000 claims description 31
- 238000004873 anchoring Methods 0.000 claims description 25
- 108091007433 antigens Proteins 0.000 claims description 25
- 102000036639 antigens Human genes 0.000 claims description 25
- 230000001580 bacterial effect Effects 0.000 claims description 24
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 150000007523 nucleic acids Chemical class 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 239000000427 antigen Substances 0.000 claims description 23
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 22
- 239000012634 fragment Substances 0.000 claims description 22
- 230000027455 binding Effects 0.000 claims description 21
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 20
- 210000004899 c-terminal region Anatomy 0.000 claims description 16
- 230000003248 secreting effect Effects 0.000 claims description 16
- 241000191967 Staphylococcus aureus Species 0.000 claims description 15
- 230000028327 secretion Effects 0.000 claims description 12
- 229960002685 biotin Drugs 0.000 claims description 11
- 235000020958 biotin Nutrition 0.000 claims description 11
- 239000011616 biotin Substances 0.000 claims description 11
- 229960005486 vaccine Drugs 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 8
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 claims description 7
- 241000191940 Staphylococcus Species 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 230000037361 pathway Effects 0.000 claims description 5
- 230000001131 transforming effect Effects 0.000 claims description 5
- 102000003992 Peroxidases Human genes 0.000 claims description 4
- 101150115929 Usp45 gene Proteins 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 4
- 230000009466 transformation Effects 0.000 claims description 4
- 238000011144 upstream manufacturing Methods 0.000 claims description 4
- 240000003291 Armoracia rusticana Species 0.000 claims description 3
- 235000011330 Armoracia rusticana Nutrition 0.000 claims description 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 241000193403 Clostridium Species 0.000 claims description 3
- 235000019687 Lamb Nutrition 0.000 claims description 3
- 108060001084 Luciferase Proteins 0.000 claims description 3
- 239000005089 Luciferase Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 108091008324 binding proteins Proteins 0.000 claims description 3
- 108091006047 fluorescent proteins Proteins 0.000 claims description 3
- 102000034287 fluorescent proteins Human genes 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 230000002163 immunogen Effects 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 244000052769 pathogen Species 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 244000063299 Bacillus subtilis Species 0.000 claims description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 2
- 241000186216 Corynebacterium Species 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 230000001568 sexual effect Effects 0.000 claims description 2
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 241000178948 Lactococcus sp. Species 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 244000057717 Streptococcus lactis Species 0.000 description 57
- 235000014897 Streptococcus lactis Nutrition 0.000 description 47
- 241000894006 Bacteria Species 0.000 description 33
- 108020004414 DNA Proteins 0.000 description 20
- 239000012528 membrane Substances 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 15
- 210000004379 membrane Anatomy 0.000 description 14
- 238000003752 polymerase chain reaction Methods 0.000 description 14
- 241000192125 Firmicutes Species 0.000 description 13
- 108090000988 Lysostaphin Proteins 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 241000194036 Lactococcus Species 0.000 description 11
- 239000003656 tris buffered saline Substances 0.000 description 11
- 238000010367 cloning Methods 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 7
- 108010052285 Membrane Proteins Proteins 0.000 description 7
- 229940098773 bovine serum albumin Drugs 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 102000018697 Membrane Proteins Human genes 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 4
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 101000582398 Staphylococcus aureus Replication initiation protein Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 238000005336 cracking Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 241000032203 Conus aureus Species 0.000 description 3
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 3
- 108010013639 Peptidoglycan Proteins 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 3
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 3
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000003100 immobilizing effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 101710116435 Outer membrane protein Proteins 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 2
- 241000191973 Staphylococcus xylosus Species 0.000 description 2
- 241000194026 Streptococcus gordonii Species 0.000 description 2
- 241000723792 Tobacco etch virus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 108010044241 tetanus toxin fragment C Proteins 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 241000363697 Corynebacterium lactis Species 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 101000582941 Homo sapiens Placenta-expressed transcript 1 protein Proteins 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 101710198693 Invasin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108010079246 OMPA outer membrane proteins Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102100030305 Placenta-expressed transcript 1 protein Human genes 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 230000021839 RNA stabilization Effects 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 101000865057 Thermococcus litoralis DNA polymerase Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 108091008394 cellulose binding proteins Proteins 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012769 display material Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000005255 gram-positive cell Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 229940041028 lincosamides Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- MXHCPCSDRGLRER-UHFFFAOYSA-N pentaglycine Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(O)=O MXHCPCSDRGLRER-UHFFFAOYSA-N 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102220219006 rs1060501597 Human genes 0.000 description 1
- -1 salts Nucleic acids Chemical class 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/16—Enzymes or microbial cells immobilised on or in a biological cell
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ベクターをグラム陽性細菌宿主に形質転換し、融合タンパク質を発現させ ると、目的とするタンパク質またはポリペプチドが宿主の細胞壁の外表面に付着 しディスプレイするように、分泌シグナル配列、目的とするタンパク質またはポ リペプチドおよび細胞壁付着ドメインからなる融合タンパク質をコード化する核 酸を含む組換ベクター。 2.該グラム陽性宿主生物体がラクトコッカス種、バシラス サチリス、スト レプトコッカス ゴルドニィ、スタフィロコッカス キシローサス、ラクトバシ ラス種、属バシラス種、クロストリジウム種またはコリネバクテリウム種の好冷 及び低温種である、請求の範囲第1項に記載の組換ベクター。 3.該グラム陽性宿主生物体がラクトコッカス宿主、好ましくはラクトコッカ ス ラクチスである、請求の範囲第2項に記載の組換ベクター。 4.該分泌シグナル配列が分泌の第二依存経路を介して分泌を目的とするタン パク質をターゲティングすることができ、天然に分泌されるタンパク質のシグナ ル配列由来である、請求の範囲第1項から第3項のいずれかに記載の組換ベクタ ー。 5.該分泌シグナル配列がタンパク質usp45のシグナル配列由来である、 請求の範囲第4項に記載の組換ベクター。 6.該細胞壁付着ドメインが少なくともスタフィロコッカス アウレウスプロ テインA由来のC−末端固着ドメインからなる、請求の範囲第1項から第5項の いずれかに記載の組換ベクター。 7.該融合タンパク質をコード化する核酸は発現させる制御配列に操作により 連結される、請求の範囲第1項から第6項のいずれかに記載の組換ベクター。 8.該核酸は融合タンパク質をコード化する核酸の上流に形成される誘導プロ モーターの制御下のT7またはT7様ポリメラーゼ遺伝子からなる、請求の範囲 第7項に記載の組換ベクター。 9.請求の範囲第1項から第8項のいずれかに記載の組換ベクターで形質転換 されるグラム陽性宿主生物体。 10.目的とするタンパク質またはポリペプチドを予め発現させ、細胞壁に共有 結合により付着させ、宿主生物体の表面に外面でディスプレイさせる、請求の範 囲第9項に記載のグラム陽性宿主生物体。 11.細胞壁固着ドメインにより宿主は目的とするタンパク質またはポリペプチ ドを細胞壁表面に付着させディスプレイすることができる、グラム陽性宿主が融 合タンパク質を発現できるように、分泌シグナル配列、目的とするタンパク質ま たはポリペプチドおよび細胞壁付着ドメインからなる融合タンパク質をコード化 する組換核酸をグラム陽性宿主生物体に形質転換することからなる、目的とする タンパク質またはポリペプチドを宿主表面上でディスプレイするためのグラム陽 性宿主生物体の操作方法。 12.請求の範囲第2項から第8項のいずれか一以上の態様によって修飾される 請求の範囲第11項に記載の方法。 13.請求の範囲第11項または第12項に記載の方法によって得られるグラム 陽性宿主生物体。 14.該目的とするタンパク質またはポリペプチドが免疫反応を生じさせること を目的とする少なくとも一のエピトープを含む、請求の範囲第9項または第10 項に記載のグラム陽性宿主生物体。 15.該目的とするタンパク質またはポリペプチドが病原体の免疫原、抗原また は付着因子である、請求の範囲第14項に記載のグラム陽性宿主生物体。 16.適当な担体との混合物における請求の範囲第14項に記載のグラム陽性宿 主生物体からなるワクチン。 17.ワクチンの調製における請求の範囲第14項または第15項に記載のグラ ム陽性宿主生物体の使用。 18.該目的とするタンパク質またはポリペプチドがそれに対して耐性を誘発さ せることを目的とするものである、請求の範囲第9項または第10項に記載のグ ラム陽性宿主生物体。 19.タンパク質またはポリペプチドに対する耐性の誘発における請求の範囲第 18項に記載のグラム陽性宿主生物体の使用。 20.該目的とするタンパク質またはポリペプチドが生物学的に活性を有する分 子である、請求の範囲第9項または第10項に記載のグラム陽性宿主生物体。 21.該生物学的に活性を有する分子が薬剤、ホルモン、酵素、DNA/RNA 結合タンパク質、または他の一緒に発現及び分泌されるタンパク質に二次的な修 飾を行える物質である、請求の範囲第20項に記載のグラム陽性宿主生物体。 22.該目的とするタンパク質またはポリペプチドが宿主生物体をターゲット部 位に結合させることができるターゲット基である、請求の範囲第9項または第1 0項に記載のグラム陽性宿主生物体。 23.該ターゲット基がターゲットされる抗原またはハプテンに結合できる、抗 体、またはその断片、または付着因子である、請求の範囲第20項に記載のグラ ム陽性宿主生物体。 24.請求の範囲第9項、第10項、または第18項から第23項のいずれかに 記載のグラム陽性宿主生物体からなる薬剤組成物。 25.薬剤に使用される請求の範囲第9項、第10項、第13項から第15項、 または第18項から第23項のいずれかに記載のグラム陽性宿 主生物体。 26.該目的とするタンパク質またはポリペプチドがリガンドの特異的な結合パ ートナーである、請求の範囲第9項または第10項に記載のグラム陽性宿主生物 体。 27.該リガンドが宿主生物体がその上に固定化されるように固体表面に結合さ れるものである、請求の範囲第26項に記載のグラム陽性宿主生物体。 28.該目的とするタンパク質またはポリペプチドがストレプトアビジンであり 、該リガンドがビオチンまたはビオチン結合体、例えば、ビオチン化西洋ワサビ のペルオキシダーゼ等のビオチン化酵素である、請求の範囲第27項に記載のグ ラム陽性宿主生物体。 29.グラム陽性宿主生物体をリガンドを予め固定した表面と接触させることか らなる、請求の範囲第26項から第28項のいずれかに記載のグラム陽性宿主生 物体の固定化方法。 30.リガンドの精製または分離における請求の範囲第26項から第28項のい ずれかに記載のグラム陽性宿主生物体の使用。 31.核酸が発現の際にレポーター活性を生じさせる遺伝子からさらになる、特 異的なリガンドを有する複合体の検出における請求の範囲第9項または第10項 に記載のグラム陽性宿主生物体の使用。 32.該レポーター活性が蛍光タンパク質またはルシフェラーゼであり、該目的 とするタンパク質がストレプトアビジンである、請求の範囲第31項に記載の使 用。 33.該目的とするタンパク質またはポリペプチドが酵素である、請求の範囲第 9項または第10項に記載のグラム陽性宿主生物体。 34.該酵素は予め発現され、宿主生物体の細胞表面上でディスプレイされる、 請求の範囲第33項に記載のグラム陽性宿主生物体からなる組 成物。 35.反応によって触媒される反応における請求の範囲第33項に記載の組成物 の使用。 36.グラム陽性宿主生物体に物質及び細胞壁固着ドメインの融合物をコード化 する核酸を形質転換し、該融合物を細胞表面上で発現させる段階からなる、物質 のライブラリーのスクリーニング方法。 37.該物質が抗体または抗原またはこれらの断片である、請求の範囲第36項 に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9518323.2 | 1995-09-07 | ||
GBGB9518323.2A GB9518323D0 (en) | 1995-09-07 | 1995-09-07 | Materials and methods relating to the attachment and display of substances on cell surfaces |
PCT/GB1996/002195 WO1997009437A1 (en) | 1995-09-07 | 1996-09-06 | Materials and methods relating to the attachment and display of substances on cell surfaces |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11511983A true JPH11511983A (ja) | 1999-10-19 |
JP4180111B2 JP4180111B2 (ja) | 2008-11-12 |
Family
ID=10780370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51098397A Expired - Fee Related JP4180111B2 (ja) | 1995-09-07 | 1996-09-06 | 細胞表面における物質の付着およびディスプレイに関連する材料および方法 |
Country Status (17)
Country | Link |
---|---|
US (1) | US6190662B1 (ja) |
EP (1) | EP0848756B1 (ja) |
JP (1) | JP4180111B2 (ja) |
KR (1) | KR19990044528A (ja) |
CN (1) | CN1201493A (ja) |
AT (1) | ATE270337T1 (ja) |
AU (1) | AU729449B2 (ja) |
BR (1) | BR9610133A (ja) |
CA (1) | CA2231372A1 (ja) |
DE (1) | DE69632827T2 (ja) |
GB (1) | GB9518323D0 (ja) |
HK (1) | HK1014337A1 (ja) |
MX (1) | MX9801864A (ja) |
NO (1) | NO980976L (ja) |
NZ (1) | NZ316580A (ja) |
WO (1) | WO1997009437A1 (ja) |
ZA (1) | ZA967562B (ja) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5821088A (en) * | 1990-05-11 | 1998-10-13 | Siga Pharmaceuticals, Inc. | Use of gram-positive bacteria to express recombinant proteins |
GB9521568D0 (en) * | 1995-10-20 | 1995-12-20 | Lynxvale Ltd | Delivery of biologically active polypeptides |
DE19735105A1 (de) * | 1997-08-13 | 1999-03-04 | Univ Albert Ludwigs Freiburg | Transportsystem zur Einbringung von Proteinen in Zielzellen mit Hilfe eines Fusionsproteins, Nucleinsäurekonstrukte kodierend für die Komponenten des Transportsystems und Arzneimittel, die Komponenten des Transportsystems umfassen |
EP0916726A1 (en) * | 1997-11-13 | 1999-05-19 | Rijksuniversiteit te Groningen | Attaching substances to micro-organisms |
US6100388A (en) * | 1998-03-16 | 2000-08-08 | Biogaia Biologies Ab | Lactobacilli harboring aggregation gene as a vaccine delivery vehicle |
AU4531899A (en) * | 1998-06-25 | 2000-01-10 | Chul-Joong Kim | Surface expression system of hepatitis b virus surface antigen and core antigen of hepatitis c virus by using ice-nucleation protein |
KR100313135B1 (ko) | 1999-02-22 | 2001-11-05 | 윤덕용 | 세포 표면 발현 모체로서의 대장균 유래 세포외막 단백질 c(o |
US7220418B1 (en) | 1999-07-05 | 2007-05-22 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Delivery of trefoil peptides |
JP2004514424A (ja) * | 2000-09-25 | 2004-05-20 | ソシエテ デ プロデユイ ネツスル ソシエテ アノニム | アレルギー反応を起こす個人の傾向を減少させることができる乳酸菌 |
EP1343894A4 (en) * | 2000-11-02 | 2005-05-04 | Univ Singapore | AOPB GENE, PROTEIN, HOMOLOGISTS, FRAGMENTS AND VARIANTS THEREOF, AND THE USE THEREOF FOR PRESENTATION ON THE CELL SURFACE |
EP1239032A1 (en) | 2001-03-02 | 2002-09-11 | Société des Produits Nestlé S.A. | Lactic acid bacteria as agents for treating and preventing allergy |
US7780961B2 (en) * | 2001-05-03 | 2010-08-24 | Actogenix N.V. | Self-containing Lactococcus strain |
WO2004001020A2 (en) * | 2002-06-19 | 2003-12-31 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Methods and means to promote gut absorption |
US7527966B2 (en) * | 2002-06-26 | 2009-05-05 | Transgenrx, Inc. | Gene regulation in transgenic animals using a transposon-based vector |
WO2004041865A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Stabilized single domain antibodies |
EP2267032A3 (en) | 2002-11-08 | 2011-11-09 | Ablynx N.V. | Method of administering therapeutic polypeptides, and polypeptides therefor |
CA2506031A1 (en) * | 2002-11-15 | 2004-06-03 | Vib Vzw | Self-containing lactobacillus strain comprising a thya mutation and therapeutic applications thereof |
US7754467B2 (en) * | 2003-01-29 | 2010-07-13 | Osel, Inc. | Surface expression of biologically active proteins in bacteria |
WO2005029078A1 (en) * | 2003-09-17 | 2005-03-31 | Guava Technologies, Inc. | Compositions and methods for analysis of target analytes |
WO2006083516A2 (en) * | 2005-01-12 | 2006-08-10 | Osel, Inc. | Modified cyanovirin-n polypeptide |
JP5410759B2 (ja) | 2005-11-29 | 2014-02-05 | アクトジェニックス・エヌブイ | 抗原に対する粘膜寛容の誘導 |
EP2774621B1 (en) | 2007-01-25 | 2018-01-24 | Intrexon Actobiotics NV | Treatment of immune disease by mucosal delivery of antigens |
EP1972350A1 (en) * | 2007-03-20 | 2008-09-24 | Rijksuniversiteit Groningen | Dual targeting system |
US20110189236A1 (en) * | 2008-05-08 | 2011-08-04 | Emory University | Methods and Compositions for the Display of Polypeptides on the Pili of Gram-Positive Bacteria |
EP2344626B1 (en) * | 2008-09-29 | 2017-03-29 | Intrexon Actobiotics NV | Reduced colonization of microbes at the mucosa |
US9861693B2 (en) | 2012-09-07 | 2018-01-09 | Emory University | HIV immune stimulating compositions comprising recombinantly expressed pili on bacteria and methods related thereto |
US9452205B2 (en) * | 2012-09-24 | 2016-09-27 | Montana State University | Recombinant Lactococcus lactis expressing Escherichia coli colonization factor antigen I (CFA/I) fimbriae and their methods of use |
EP4221730A1 (en) * | 2020-12-23 | 2023-08-09 | Chan Zuckerberg Biohub, Inc. | Bacteria-engineered to elicit antigen-specific t cells |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5616686A (en) | 1990-05-11 | 1997-04-01 | The Rockefeller University | Polypeptide of a hybrid surface protein by bacteria |
US5348867A (en) * | 1991-11-15 | 1994-09-20 | George Georgiou | Expression of proteins on bacterial surface |
CA2131995A1 (en) * | 1992-03-13 | 1993-09-16 | Vincent A. Fischetti | Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria |
-
1995
- 1995-09-07 GB GBGB9518323.2A patent/GB9518323D0/en active Pending
-
1996
- 1996-09-06 DE DE69632827T patent/DE69632827T2/de not_active Expired - Lifetime
- 1996-09-06 BR BR9610133-4A patent/BR9610133A/pt not_active Application Discontinuation
- 1996-09-06 EP EP96929431A patent/EP0848756B1/en not_active Expired - Lifetime
- 1996-09-06 NZ NZ316580A patent/NZ316580A/en not_active IP Right Cessation
- 1996-09-06 CA CA002231372A patent/CA2231372A1/en not_active Abandoned
- 1996-09-06 ZA ZA9607562A patent/ZA967562B/xx unknown
- 1996-09-06 AU AU68844/96A patent/AU729449B2/en not_active Ceased
- 1996-09-06 CN CN96198087A patent/CN1201493A/zh active Pending
- 1996-09-06 JP JP51098397A patent/JP4180111B2/ja not_active Expired - Fee Related
- 1996-09-06 AT AT96929431T patent/ATE270337T1/de not_active IP Right Cessation
- 1996-09-06 KR KR1019980701776A patent/KR19990044528A/ko not_active Application Discontinuation
- 1996-09-06 WO PCT/GB1996/002195 patent/WO1997009437A1/en active IP Right Grant
-
1998
- 1998-03-06 NO NO980976A patent/NO980976L/no unknown
- 1998-03-06 US US09/036,609 patent/US6190662B1/en not_active Expired - Lifetime
- 1998-03-09 MX MX9801864A patent/MX9801864A/es unknown
- 1998-12-24 HK HK98115718A patent/HK1014337A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE69632827D1 (de) | 2004-08-05 |
DE69632827T2 (de) | 2005-07-07 |
ZA967562B (en) | 1998-03-06 |
US6190662B1 (en) | 2001-02-20 |
MX9801864A (es) | 1998-11-29 |
ATE270337T1 (de) | 2004-07-15 |
NO980976L (no) | 1998-05-06 |
BR9610133A (pt) | 1999-12-21 |
GB9518323D0 (en) | 1995-11-08 |
KR19990044528A (ko) | 1999-06-25 |
NZ316580A (en) | 1999-09-29 |
AU729449B2 (en) | 2001-02-01 |
NO980976D0 (no) | 1998-03-06 |
EP0848756A1 (en) | 1998-06-24 |
AU6884496A (en) | 1997-03-27 |
CN1201493A (zh) | 1998-12-09 |
JP4180111B2 (ja) | 2008-11-12 |
EP0848756B1 (en) | 2004-06-30 |
WO1997009437A1 (en) | 1997-03-13 |
CA2231372A1 (en) | 1997-03-13 |
HK1014337A1 (en) | 1999-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4180111B2 (ja) | 細胞表面における物質の付着およびディスプレイに関連する材料および方法 | |
AU770674B2 (en) | Recombinant phages capable of entering host cells via specific interaction with an artificial receptor | |
Click et al. | Filamentous phage infection: required interactions with the TolA protein | |
US5348867A (en) | Expression of proteins on bacterial surface | |
JP3865792B2 (ja) | ペプチド、融合ペプチド、発現ベクター及び組換えタンパク質の製造方法 | |
JPH07502640A (ja) | シグナルペプチド、選択的相互作用ポリペプチド及び膜固定配列をコードする組換えdna配列 | |
US7858357B2 (en) | Immunization with bacterial ghost-based vaccines | |
AU2006270565B2 (en) | Bifunctional protein anchors | |
JP5787298B2 (ja) | 膜に提示したタンパク質を特異的に認識するポリペプチドの調製方法 | |
JP2007503845A (ja) | 細菌における生物学的に活性なタンパク質の表面発現 | |
AU633842B2 (en) | Recombinant systems for expression of cholera b-subunit with the aid of foreign promoters and/or leader peptides | |
US7060462B2 (en) | AopB gene, protein,homologs, fragments and variants thereof, and their use for cell surface display | |
Ludwig et al. | Haemolysins of Escherichia coli | |
Meyer et al. | Autodisplay: Functional Display of Active | |
JP2009118759A (ja) | ヒト癌細胞選択的な細胞障害能を有する新規タンパク質 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060516 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060731 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060915 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061115 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070220 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20070201 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070508 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20070903 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20070903 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080729 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080827 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110905 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |